2cureX was founded in 2006 with the vision of improving treatment efficiency of cancer patients. From the onset, 2cureX has been closely integrated with the cancer hospitals in the Copenhagen area. This has since been expanded to include hospitals in Germany and United Kingdom. Furthermore, we have successfully lead multiple collaborations with both commercial and academic partners. 2cureX has since its inception raised over €7 million in both national and international grants and private investments. 2cureX has developed the IndiTreat™, which has been developed and tested in more than 900 patients with promising results. 2cureX has in October 2017 started a clinical trial using IndiTreat™ with stage IV colorectal cancer patients.
What have been the milestones so far in your company development?
As CEO I’m very proud that we as a company delivered on our 2018 Goals that we presented at the IPO in November 2017. It is fantastic to see that we with a dedicated team also kept the pace going in the first half of 2019. Some key achievements in 2019 that I really would like to mention are; 1. The presentation of our positive Interim clinical results in Colorectal Cancer 2. 2cureX collaboration with Gibson Oncology 3. Signed agreement with the largest Private Cancer Center in the Nordics
What are your most important markets, segments and customers?
Our most important markets are at this moment the Big 5 European markets, where we focus on Larger Regional Hospitals, Private Cancer Clinics and commercial diagnostic labs. The market segment we aim for are cancer patients within Colorectal Cancer, Ovarian Cancer and Pancreatic Cancer in need of Medical Treatment.
Where do you see the company five years from now?
In five years from now IndiTreat will be a more established test within cancer treatment and recommended in guidelines in order to determine a patient’s tumor Resistance/Sensitivity to different treatments.
What are your priorities within 2020/21?
The priorities for the company in 20/21 are securing a successful product launch in 2020 and delivering sales revenue
Why should one consider adding your company into their portfolio?
2cureX is an investment that has shown in the past year that it delivers on its goals and strategy and a company very close to commercialization. The investment is Low Risk and with Solid gain per share